Drugs / TGFBR2 KO CAR27/IL-15 NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06930651 | Sep 2025 → May 2028 expected | myeloid neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGFBR2 KO CAR27/IL-15 NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06930651 ↗ |
| Action | Inhibit | “TGFBR2 KO” NCT06930651 ↗ |
| Modality | Cell therapy | “one-time infusion of the CAR.70/IL15-transduced/TGFBR2KO CB-NK cells” NCT06930651 ↗ |
| Route | Other | “Given by Infusion” NCT06930651 ↗ |
| Target | TGFBR2 | “TGFBR2 KO” NCT06930651 ↗ |